Clinical Trials Browser

Phase 1/2 × Recruiting × Ivermectin × Clear all

NCT05318469 2026-05-06

Ivermectin in Combination With Balstilimab or Pembrolizumab in Patients With Metastatic Triple Negative Breast Cancer

Phase 1/2 Recruiting

Triple Negative Breast Neoplasms